KLK3 and neoplasm: Furthermore, the availability of prostate-specific antigen (PSA) levels provides an accessible and widely accepted marker of tumor burden in this context (Adhyam and Gupta 2012; de Bono et al. 2011) and allows regular and non-invasive tracking of tumor size to inform the AT protocol.